Rigel Pharmaceuticals (RIGL) Resumen de Acciones
Rigel Pharmaceuticals, Inc, empresa de biotecnología, desarrolla y suministra terapias que mejoran la vida de los pacientes con trastornos hematológicos y cáncer en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
RIGL Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Rigel Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$39.12 |
| Máximo en las últimas 52 semanas | US$52.24 |
| Mínimo de 52 semanas | US$18.24 |
| Beta | 1.18 |
| Cambio en 1 mes | 28.30% |
| Variación en 3 meses | 42.25% |
| Cambio de 1 año | 109.09% |
| Variación en 3 años | 198.63% |
| Variación en 5 años | -11.49% |
| Variación desde la OPV | -93.89% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 30
RIGL: Veppanu In Licensing And Ex U.S. Breast Cancer Expansion Will Drive Repricing
Rigel Pharmaceuticals' fair value estimate has been revised to $81 from $71 as analysts factor in the Veppanu in-licensing and the broader ex U.S. Rezlidhia opportunity in their updated assumptions. Analyst Commentary Recent research coverage on Rigel Pharmaceuticals has centered on the Veppanu in-licensing and the expanding ex U.S. opportunity for Rezlidhia, with several bullish analysts highlighting these moves as key drivers in their updated views on valuation and execution risk.Seeking Alpha • Jun 20
A Look At The Transformation Around Rigel Pharmaceuticals
Summary Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million. An updated analysis around Rigel Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 16
RIGL: Breast Cancer Launch Will Drive Future Upside Potential
Analysts nudged their price target on Rigel Pharmaceuticals higher to $81 from $69, citing the Veppanu in-licensing agreement and the expanding Rezlidhia partnership footprint as key drivers behind their updated view. Analyst Commentary Recent research on Rigel Pharmaceuticals has centered on two main themes: the expanding reach of Rezlidhia outside the U.S. and the Veppanu licensing deal with Pfizer and Arvinas.Actualización de narrativa • Jun 02
RIGL: Breast Cancer Launch And Ex U S Expansion Will Shape Future Upside
Analysts raised their price targets on Rigel Pharmaceuticals, including Citi's increase from $69 to $81 per share. They cited the Veppanu in-licensing and the Rezlidhia ex U.S. NDA as key reasons for their revised views.Recent updates
Actualización de narrativa • Jun 30
RIGL: Veppanu In Licensing And Ex U.S. Breast Cancer Expansion Will Drive Repricing
Rigel Pharmaceuticals' fair value estimate has been revised to $81 from $71 as analysts factor in the Veppanu in-licensing and the broader ex U.S. Rezlidhia opportunity in their updated assumptions. Analyst Commentary Recent research coverage on Rigel Pharmaceuticals has centered on the Veppanu in-licensing and the expanding ex U.S. opportunity for Rezlidhia, with several bullish analysts highlighting these moves as key drivers in their updated views on valuation and execution risk.Seeking Alpha • Jun 20
A Look At The Transformation Around Rigel Pharmaceuticals
Summary Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing strong Tavalisse performance and recent product acquisitions. Q1 revenues rose 10% year-over-year to $58.8 million, but net product revenues rose 26%; management also maintained FY2026 sales guidance of $275–$290 million. An updated analysis around Rigel Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaActualización de narrativa • Jun 16
RIGL: Breast Cancer Launch Will Drive Future Upside Potential
Analysts nudged their price target on Rigel Pharmaceuticals higher to $81 from $69, citing the Veppanu in-licensing agreement and the expanding Rezlidhia partnership footprint as key drivers behind their updated view. Analyst Commentary Recent research on Rigel Pharmaceuticals has centered on two main themes: the expanding reach of Rezlidhia outside the U.S. and the Veppanu licensing deal with Pfizer and Arvinas.Actualización de narrativa • Jun 02
RIGL: Breast Cancer Launch And Ex U S Expansion Will Shape Future Upside
Analysts raised their price targets on Rigel Pharmaceuticals, including Citi's increase from $69 to $81 per share. They cited the Veppanu in-licensing and the Rezlidhia ex U.S. NDA as key reasons for their revised views.Actualización de narrativa • May 13
RIGL: Execution On Breast Cancer Franchise Will Shape Future Upside Potential
Analysts trimmed their price target on Rigel Pharmaceuticals by $2 as they factor in updated views on growth, profitability and future P/E multiples, even while recent commentary suggests Pfizer's handoff of Veppanu to Rigel could support the company's long term positioning. Analyst Commentary Recent Street views on Rigel Pharmaceuticals highlight a mix of longer term opportunity around Veppanu and nearer term caution on execution, growth visibility and valuation.Artículo de análisis • May 12
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position
The latest earnings release from Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) disappointed investors. We did some...Actualización de narrativa • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.Actualización de narrativa • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.Actualización de narrativa • Mar 31
RIGL: Higher Future P/E Assumptions Will Support Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts describe the latest US$2 increase in the price target as a reflection of refreshed assumptions on discount rates, revenue potential, and profitability for Rigel Pharmaceuticals.Actualización de narrativa • Mar 17
RIGL: Margin Improvement Execution Will Shape Future Upside Potential
Analysts have increased their price target on Rigel Pharmaceuticals by $2, reflecting updated views on slightly adjusted growth assumptions, a modestly higher discount rate, and expectations for improved profit margins alongside a lower future P/E. Analyst Commentary Recent research around Rigel Pharmaceuticals points to a mixed setup, where the updated price target and refined assumptions are paired with a clear emphasis on execution and margin discipline.
Actualización de narrativa • Mar 03
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.Actualización de narrativa • Feb 17
RIGL: Updated Earnings Outlook And P/E Assumptions Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals by $2 to $71, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has leaned positive, with bullish analysts using the higher fair value estimate and updated P/E assumptions to support their case for upside potential.Actualización de narrativa • Feb 03
RIGL: Higher 2025 Sales Guidance And Execution Will Shape Future Upside And Risks
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals from $23 to $38 per share, pointing to raised Street price targets, stronger recent product sales versus expectations, higher 2025 sales guidance in the US$225m to US$230m range, solid commercial execution, improving profitability assumptions and a higher future P/E multiple. Analyst Commentary Recent Street research has highlighted Rigel Pharmaceuticals' stronger product sales versus expectations and higher 2025 net product sales guidance in the US$225m to US$230m range, alongside raised price targets in some cases.Actualización de narrativa • Jan 19
RIGL: Future Returns Will Reflect Raised 2025 Sales Guidance And Positive Cash Flow
Analysts have nudged their fair value estimate for Rigel Pharmaceuticals slightly higher to US$51.60 from US$51.20, citing recent price target increases and upgrades that highlight strong commercial execution, improved 2025 net product sales guidance to US$225m to US$230m, positive cash flow, and potential for further business development. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has focused on how the company is executing against its guidance and what that might mean for valuation.Artículo de análisis • Jan 08
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Actualización de narrativa • Jan 05
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts nudged their fair value estimate for Rigel Pharmaceuticals higher from US$49.60 to US$51.20, citing stronger Q3 product sales, increased 2025 net product sales guidance to US$225m to US$230m, improved profit margin assumptions and a slightly lower future P/E multiple following recent research upgrades. Analyst Commentary Recent research updates point to a constructive shift in sentiment around Rigel Pharmaceuticals, driven by Q3 performance and revised 2025 guidance.Actualización de narrativa • Dec 20
RIGL Q3 Execution And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by about $2 to reflect stronger expected revenue growth, higher profit margins, and improved commercial execution highlighted by recent Street research. Analyst Commentary Bullish analysts have highlighted Rigel Pharmaceuticals as a compelling growth story in the mid-cap biotech space, pointing to recent guidance increases and stronger than expected product sales as key drivers of renewed enthusiasm.Actualización de narrativa • Dec 06
RIGL: Future Results Will Reflect Sustained Execution Amid Emerging Commercial And Pipeline Milestones
Analysts have raised their price target for Rigel Pharmaceuticals by $3, increasing it to $49.60 from $46.60. This change reflects increased confidence in stronger revenue growth, higher profit margins and solid commercial execution highlighted in recent research.Artículo de análisis • Nov 27
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Nov 22
RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance
Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.Artículo de análisis • Nov 12
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...Actualización de narrativa • Nov 07
RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast
Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.Artículo de análisis • Sep 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Key Insights The projected fair value for Rigel Pharmaceuticals is US$39.23 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • Sep 25
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 26% in the last month, reversing a fair...Artículo de análisis • Sep 03
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Aug 07
Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).Artículo de análisis • Aug 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:RIGL 1 Year Share Price vs Fair Value Explore Rigel Pharmaceuticals's Fair Values from the Community and...Artículo de análisis • May 15
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Rigel Pharmaceuticals will host its Annual General Meeting on 22nd of May Total pay for CEO Raul Rodriguez...Artículo de análisis • May 09
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) defied analyst predictions to release its first-quarter results, which were...Artículo de análisis • Apr 02
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 11
Rigel Looks Interesting, But Let's Wait For A Lower Price
Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-risk myelodysplastic syndromes, with good safety and efficacy profiles. Rigel has a strong financial position with a market cap of $366mn, $77mn cash, and projected 2025 revenue of $200-$210 million. Despite positive financials and promising drug data, since RIGL is trading at a 52-week high, I recommend waiting for a lower price to buy. Read the full article on Seeking Alpha
Nueva narrativa • Feb 09
Advancing Pipeline And Partnerships Will Drive Future Success
Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.Artículo de análisis • Feb 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have continued their recent momentum with a 38% gain in the last...Artículo de análisis • Dec 20
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 28% in the last month, reversing a fair...Rentabilidad de los accionistas
| RIGL | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 9.9% | 5.1% | 1.9% |
| 1Y | 109.1% | 40.0% | 20.3% |
Rentabilidad vs. Industria: RIGL superó a la industria US Biotechs, que obtuvo un rendimiento del 40% el año pasado.
Rentabilidad vs. Mercado: RIGL superó al mercado US, que obtuvo un rendimiento del 20.3% el año pasado.
Volatilidad de los precios
| RIGL volatility | |
|---|---|
| RIGL Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: RIGL no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de RIGL (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 173 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc, empresa de biotecnología, desarrolla y suministra terapias que mejoran la vida de los pacientes con trastornos hematológicos y cáncer en Estados Unidos. La empresa ofrece TAVALISSE, un inhibidor oral de la tirosina cinasa del bazo para el tratamiento de pacientes adultos con trombocitopenia inmunitaria crónica; REZLIDHIA, una monoterapia no intensiva para tratar a pacientes adultos con leucemia mieloide aguda (LMA) recidivante o resistente al tratamiento (R/R) con una mutación susceptible de la isocitrato deshidrogenasa-1 (IDH1) detectada mediante una prueba aprobada por la FDA; y GAVRETO, un inhibidor de la cinasa, oral, de molécula pequeña, administrado una vez al día, para el tratamiento de pacientes adultos con cáncer de pulmón no microcítico (CPNM) metastásico positivo a la fusión reordenada durante la transfección (RET), así como para tratar a pacientes adultos y pediátricos de doce años o más con cáncer de tiroides avanzado o metastásico positivo a la fusión RET. También desarrolla el R289, un inhibidor oral de las quinasas 1 y 4 asociadas a receptores de interleucina (IRAK1/4), que está en fase 1b de estudio para el tratamiento de enfermedades hemato-oncológicas, autoinmunes e inflamatorias, así como para tratar el síndrome mielodisplásico de bajo riesgo.
Resumen de fundamentos de Rigel Pharmaceuticals, Inc.
| Estadísticas fundamentales de RIGL | |
|---|---|
| Capitalización bursátil | US$722.32m |
| Beneficios(TTM) | US$364.23m |
| Ingresos (TTM) | US$299.77m |
2.0x
Ratio precio-beneficio (PE)2.4x
Ratio precio-ventas (PS)¿Está RIGL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RIGL | |
|---|---|
| Ingresos | US$299.77m |
| Coste de los ingresos | US$56.35m |
| Beneficio bruto | US$243.41m |
| Otros gastos | -US$120.82m |
| Beneficios | US$364.23m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 19.69 |
| Margen bruto | 81.20% |
| Margen de beneficio neto | 121.51% |
| Ratio deuda/patrimonio | 11.2% |
¿Cómo se ha desempeñado RIGL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/30 06:26 |
| Precio de las acciones al final del día | 2026/06/30 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Rigel Pharmaceuticals, Inc. está cubierta por 20 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |